<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25847" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neutrophilic Eccrine Hidradenitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Crane</surname>
            <given-names>Jonathan S.</given-names>
          </name>
          <aff>Sampson Regional Med Ctr / Campbell Univ</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krishnamurthy</surname>
            <given-names>Karthik</given-names>
          </name>
          <aff>HCA Florida Orange Park Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Crane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karthik Krishnamurthy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25847.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neutrophilic eccrine hidradenitis is an uncommon disease affecting the eccrine glands, leading to eccrine unit necrosis. It is most commonly seen in adults receiving cytarabine as a part of the induction chemotherapy for the treatment of hematological malignancy. The diagnosis of neutrophilic eccrine hidradenitis may signify that the patient has an underlying malignancy or relapse of previous malignancy. In newly diagnosed neutrophilic eccrine hidradenitis patients with no history of malignancy, the primary care provider should be notified, and age-appropriate cancer screening guidelines should be followed. This activity reviews the evaluation, treatment, and prognosis of neutrophilic eccrine hidradenitis and examines the role of the interprofessional team in evaluating and improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the risk factors for neutrophilic eccrine hidradenitis.</p></list-item><list-item><p>Review the presenting features of neutrophilic eccrine hidradenitis.</p></list-item><list-item><p>Outline the management of neutrophilic eccrine hidradenitis.</p></list-item><list-item><p>Describe how an optimally functioning interprofessional team approach to coordinate care and enhance outcomes for patients with neutrophilic eccrine hidradenitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25847&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25847">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25847.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neutrophilic eccrine hidradenitis (NEH) is a benign, rare condition that was initially used to describe the skin eruptions observed in acute myelogenous leukemia (AML) patients receiving systemic chemotherapy. It can be considered a reactive disorder and is commonly associated with malignancies that include other leukemias, Hodgkin lymphoma, and solid tumors. Since its introduction in 1982, neutrophilic eccrine hidradenitis&#x000a0;is frequently described with other neutrophilic dermatoses. these are a group of skin disorders characterized by normal neutrophilic infiltrates in the predominantly dermal portion of the skin, with no identifiable source of infection.&#x000a0;<xref ref-type="bibr" rid="article-25847.r1">[1]</xref></p>
      </sec>
      <sec id="article-25847.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Neutrophilic eccrine hidradenitis is a benign, self-limiting neutrophilic dermatosis of unknown etiology. However, neutrophilic eccrine hidradenitis&#x000a0;has been observed with the following medications: acetaminophen, minocycline, granulocyte colony-stimulating factors, cyclophosphamide, methotrexate, carbamazepine, cetuximab, BRAF inhibitors, bleomycin, methotrexate, 5-fluorouracil, and antiretroviral medications. Before&#x000a0;neutrophilic eccrine hidradenitis&#x000a0;is diagnosed, practitioners usually rule-out infectious causes; nevertheless, biopsy results from several cases of active bacterial and viral infections were reported to show histological changes consistent with neutrophilic eccrine hidradenitis. Of note, heat damage of eccrine glands may elicit neutrophilic eccrine hidradenitis&#x000a0;in the pediatric population.<xref ref-type="bibr" rid="article-25847.r1">[1]</xref><xref ref-type="bibr" rid="article-25847.r2">[2]</xref></p>
      </sec>
      <sec id="article-25847.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The frequency of neutrophilic eccrine&#x000a0;hidradenitis is not well studied&#x000a0;or known. Neutrophilic eccrine hidradenitis has a slight male predominance and has been reported in individuals between six months to 79 years of age.<xref ref-type="bibr" rid="article-25847.r2">[2]</xref></p>
      </sec>
      <sec id="article-25847.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of neutrophilic eccrine hidradenitis&#x000a0;is poorly understood. There is evidence supporting a direct cytotoxic effect of chemotherapy as the initial trigger in neutrophilic eccrine hidradenitis&#x000a0;pathophysiology. For instance, intradermal bleomycin injections caused pathologic changes consistent with those seen in neutrophilic eccrine hidradenitis. Interestingly, patients with malignancies who develop neutrophilic eccrine hidradenitis&#x000a0;typically do so after their first course of chemotherapy.<xref ref-type="bibr" rid="article-25847.r3">[3]</xref><xref ref-type="bibr" rid="article-25847.r4">[4]</xref></p>
        <p>One proposed mechanism emphasizes the direct cytotoxic effect of the offending agent. The release of toxic byproducts secondary to cell death promotes neutrophil recruitment to the eccrine glands, while another model suggests that neutrophilic eccrine hidradenitis&#x000a0;is a reactive process in response to an underlying malignancy (paraneoplastic phenomenon). Another model suggests abnormal neutrophil response and function in response to some offending agent (drug versus malignancy).<xref ref-type="bibr" rid="article-25847.r5">[5]</xref></p>
      </sec>
      <sec id="article-25847.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Biopsy specimens reveal a dense neutrophilic infiltrate surrounding and infiltrating within and around eccrine glands, with necrotic eccrine epithelial cells. Intraductal abscess formation may be seen as well. Neutropenic patients may have sparse or absence of neutrophils in the dermal layer, but eccrine gland necrosis is evident. Thus, the hallmark histological finding in neutrophilic eccrine hidradenitis&#x000a0;is necrosis of the eccrine unit.&#x000a0;Moreover, the following histological changes may also be evident in neutrophilic eccrine hidradenitis: apocrine gland necrosis, squamous syringometaplasia, dermal hemorrhage, epidermal spongiosis, basilar vacuolization, focal keratinocyte necrosis, mucin deposition, and panniculitis.<xref ref-type="bibr" rid="article-25847.r1">[1]</xref></p>
      </sec>
      <sec id="article-25847.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The classic presentation of neutrophilic eccrine hidradenitis&#x000a0;is seen in acute myelogenous leukemia patients receiving chemotherapy, most commonly with cytarabine. Neutrophilic eccrine hidradenitis&#x000a0;can present as quickly&#x000a0;as two days or up to 2 years after chemotherapy initiation. Also, there have been documented cases of neutrophilic eccrine hidradenitis&#x000a0;in acute myelogenous leukemia and chronic myelogenous leukemia (CML) patients na&#x000ef;ve to chemotherapeutic agents. Clinically patients present with erythematous papules and plaques most frequently in the face, back, trunk, and extremities.<xref ref-type="bibr" rid="article-25847.r5">[5]</xref></p>
        <p>Regardless of the patients&#x02019; past medical history, neutrophilic eccrine hidradenitis&#x000a0;patients frequently present with fever, in addition to the solitary or multiple lesions that are best described as dark red, violaceous macules, papules, nodules, or plaques.<xref ref-type="bibr" rid="article-25847.r6">[6]</xref></p>
        <p>Neutrophilic eccrine hidradenitis favors the trunk and limbs. Half the patients are asymptomatic, while lesional pain and tenderness are the most common complaints. Because of its variable presentations, it can be challenging to differentiate neutrophilic eccrine hidradenitis from other neutrophilic dermatoses that are also commonly associated with malignancies.<xref ref-type="bibr" rid="article-25847.r6">[6]</xref></p>
        <p>Neutrophilic eccrine hidradenitis differential diagnoses include, but are not limited to, other neutrophilic dermatoses such as acute febrile neutrophilic dermatosis (Sweet syndrome), acute urticaria, graft versus host disease, erythema nodosum, erythema multiforme, cellulitis, and erysipelas.<xref ref-type="bibr" rid="article-25847.r7">[7]</xref></p>
      </sec>
      <sec id="article-25847.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Definitive diagnosis of neutrophilic eccrine hidradenitis&#x000a0;requires a skin punch biopsy demonstrating a dense neutrophilic infiltrate of the eccrine unit with necrosis and dermal edema. A routine complete blood count (CBC) should be ordered to&#x000a0;confirmed neutrophilic eccrine hidradenitis&#x000a0;cases (preliminary workup for possible underlying hematological malignancy). Nonspecific inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be considered. Tissue culture is critical for detecting infectious causes.<xref ref-type="bibr" rid="article-25847.r8">[8]</xref><xref ref-type="bibr" rid="article-25847.r9">[9]</xref></p>
      </sec>
      <sec id="article-25847.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no widely accepted treated for neutrophilic eccrine hidradenitis; supportive care is recommended. In general, neutrophilic eccrine hidradenitis&#x000a0;is a self-limiting disease and does not require therapy. In most cases, the lesions resolve spontaneously within a month. The use of corticosteroids, topical and systemic, is debatable. Nonetheless, it is well-recognized that steroids should be used with caution in neutropenic patients. Symptomatic management of fever and, or, pain is strongly recommended. Colchicine has been used successfully to treat otherwise healthy, neutrophilic eccrine hidradenitis&#x000a0;patients.<xref ref-type="bibr" rid="article-25847.r10">[10]</xref></p>
        <p>Many patients experience recurrent&#x000a0;neutrophilic eccrine hidradenitis&#x000a0;with subsequent courses of chemotherapy; if the patient&#x02019;s neutrophilic eccrine hidradenitis&#x000a0;is associated with a specific chemotherapeutic agent, one case report recommends using dapsone 100 mg daily, for 48 hours, before drug rechallenge.<xref ref-type="bibr" rid="article-25847.r11">[11]</xref></p>
      </sec>
      <sec id="article-25847.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute or chronic urticaria</p>
          </list-item>
          <list-item>
            <p>Vasculitis syndrome</p>
          </list-item>
          <list-item>
            <p>Drug eruptions</p>
          </list-item>
          <list-item>
            <p>Erythema multiforme/nodosum</p>
          </list-item>
          <list-item>
            <p>Leukemia cutis&#x000a0;<xref ref-type="bibr" rid="article-25847.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25847.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Recurrence of symptoms is common in patients administered chemotherapy. However, neutrophilic eccrine hidradenitis runs a self-limited course and does not worsen the prognosis for that particular malignancy.<xref ref-type="bibr" rid="article-25847.r11">[11]</xref></p>
      </sec>
      <sec id="article-25847.s12" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Most patients need to follow up care to ensure that there is a resolution of the skin lesions.<xref ref-type="bibr" rid="article-25847.r11">[11]</xref></p>
      </sec>
      <sec id="article-25847.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>The condition is best treated by an oncologist and a dermatologist who specializes in oncology.<xref ref-type="bibr" rid="article-25847.r2">[2]</xref></p>
      </sec>
      <sec id="article-25847.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Neutrophilic eccrine hidradenitis is an uncommon disease affecting the eccrine glands, leading to eccrine unit necrosis.</p>
        <p>It is most commonly seen in adults receiving cytarabine as part of the induction chemotherapy for the&#x000a0;treatment of hematological malignancy.</p>
        <p>The diagnosis of neutrophilic eccrine hidradenitis&#x000a0;may signify that the patient has an underlying malignancy (paraneoplastic process), or relapse of previous malignancy.&#x000a0;In newly diagnosed neutrophilic eccrine hidradenitis&#x000a0;patients with no history of malignancy, their primary care provider should be notified, and age-appropriate cancer screening guidelines should be followed.&#x000a0;</p>
        <p>A skin biopsy is necessary to confirm the diagnosis of neutrophilic eccrine hidradenitis.</p>
        <p>If the patient has a cancer history, the managing hematologist, and, or oncologist should be informed.</p>
        <p>There is no widely accepted treated for neutrophilic eccrine hidradenitis; supportive care is recommended.<xref ref-type="bibr" rid="article-25847.r2">[2]</xref><xref ref-type="bibr" rid="article-25847.r12">[12]</xref></p>
      </sec>
      <sec id="article-25847.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Treatment of neutrophilic eccrine hidradenitis is supportive; usually requiring interprofessional management of clinicians of multiple specialties and supportive care of specialty-trained dermatology and oncology nurses. The nurses monitor patient's conditions, administer ordered treatments, and educate patients about skincare. Oncology pharmacists should be aware of this condition, review the use of medications with patients, and provide feedback to the team. [Level 5]</p>
      </sec>
      <sec id="article-25847.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25847&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25847">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/neutrophilic-eccrine-hidradenitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25847">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25847/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25847">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25847.s17">
        <title>References</title>
        <ref id="article-25847.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrist</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Mihm</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy.</article-title>
            <source>Arch Dermatol</source>
            <year>1982</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>263</fpage>
            <page-range>263-6</page-range>
            <pub-id pub-id-type="pmid">6950689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic dermatoses occurring in oncology patients.</article-title>
            <source>Int J Dermatol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <page-range>106-11</page-range>
            <pub-id pub-id-type="pmid">17214733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Templeton</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Swerlick</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Intradermal bleomycin injections into normal human skin. A histopathologic and immunopathologic study.</article-title>
            <source>Arch Dermatol</source>
            <year>1994</year>
            <month>May</month>
            <volume>130</volume>
            <issue>5</issue>
            <fpage>577</fpage>
            <page-range>577-83</page-range>
            <pub-id pub-id-type="pmid">7513985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Helm</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Tuthill</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic eccrine hidradenitis heralding the onset of acute myelogenous leukemia.</article-title>
            <source>Arch Dermatol</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>129</volume>
            <issue>6</issue>
            <fpage>791</fpage>
            <page-range>791-2</page-range>
            <pub-id pub-id-type="pmid">8507092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saada</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Aractingi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marinho</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frances</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>[Neutrophilic eccrine hidradenitis associated with relapse of acute myeloblastic leukemia].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>125</volume>
            <issue>6-7</issue>
            <fpage>420</fpage>
            <page-range>420-2</page-range>
            <pub-id pub-id-type="pmid">9747299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scharf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Polsky</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic eccrine hidradenitis masquerading as facial cellulitis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>693</fpage>
            <page-range>693-6</page-range>
            <pub-id pub-id-type="pmid">17109994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachmeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chaibi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aractingi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor.</article-title>
            <source>Br J Dermatol</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>139</volume>
            <issue>2</issue>
            <fpage>354</fpage>
            <page-range>354-5</page-range>
            <pub-id pub-id-type="pmid">9767267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mutasim</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Neutrophilic eccrine hidradenitis in a patient with Beh&#x000e7;et's disease.</article-title>
            <source>Cutis</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-11</page-range>
            <pub-id pub-id-type="pmid">11534910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Penven</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Comoz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cribier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dompmartin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leroy</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Neutrophilic eccrine hidradenitis in a healthy patient].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2005</year>
            <season>Aug-Sep</season>
            <volume>132</volume>
            <issue>8-9 Pt 1</issue>
            <fpage>686</fpage>
            <page-range>686-8</page-range>
            <pub-id pub-id-type="pmid">16230920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Generalized idiopathic neutrophilic eccrine hidradenitis in childhood.</article-title>
            <source>Int J Dermatol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-8</page-range>
            <pub-id pub-id-type="pmid">20465618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Copaescu</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Castilloux</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chababi-Atallah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sinave</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A classic clinical case: neutrophilic eccrine hidradenitis.</article-title>
            <source>Case Rep Dermatol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <page-range>340-6</page-range>
            <pub-id pub-id-type="pmid">24474918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25847.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sweet's syndrome revisited: a review of disease concepts.</article-title>
            <source>Int J Dermatol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>761</fpage>
            <page-range>761-78</page-range>
            <pub-id pub-id-type="pmid">14521689</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
